[Inhibition of plasmatic coagulation: what is new?].
The major goal in the development of new anticoagulant drugs is a more effective action with less adverse effects. Until now the mainly used agents are heparin and phenprocoumon or warfarin. These drugs inhibit multiple coagulation factors in different stages of the coagulation cascade. Modern drug development and the knowledge about the molecular mechanisms of the coagulation cascade allow specific inhibition of distinct phases of thrombus formation. This review focuses on the new developments in this area.
Schwarz
M
M
Abt. für Kardiologie und Angiologie, Klinikum der Albrecht-Ludwigs-Universität, Hugstetterstr. 55, 79106 Freiburg im Breisgau. schwarz@med1.ukl.uni-freiburg.de
Bode
C
C